Health Care Technology
Augere Medical Secures MDR CE-Mark For Its Polypaid Software And System
Share
The MDR CE-mark is an important milestone for Augere Medical, enabling European launch of Augere's PolypAId™ System for artificial intelligence (AI) assisted detection of polyps during colonoscopy colon cancer screening.
OSLO, Norway, Aug. 29, 2024 /PRNewswire/ -- After more than 10 years of basic research, product and clinical development, the Medical Device Regulation (MDR) CE-mark is a crucial milestone and enables Augere Medical to start commercial launch in geographies accepting the MDR CE-mark. The basic research originated from clinical needs identified by leading Scandinavian clinicians and research organizations which laid the fundament for Augere's platform for AI assisted systems.
David Borge Larsen, Augere's interim CEO, commented: "This regulatory approval for PolypAId™ is a major milestone for Augere and we have been working hard to achieving the MDR CE-mark over the last years. We are excited to start the commercialization of PolypAId™, working with clinicians and healthcare providers to augment screening of colorectal cancer and in general to increase prevention of bowel cancer and thereby improving patient care."
According to the World Health Organization, colorectal cancer (CRC) is the third most common cancer worldwide accounting for approximately 10% of all cancer cases. In 2020, more than 1.9 million new cases of CRC were reported, and more than 930,000 deaths were estimated worldwide. By 2040 the burden of CRC will increase to 3.2 million new cases per year (an increase of 63%) and 1.6 million deaths are expected per year (an increase of 73%).
Early detection of CRC and the precursors, polyps, through colonoscopy screening is regarded as the most effective way to decrease incidence rates and deaths, together with life-style changes. AI assisted colonoscopy screening enables healthcare systems to standardize polyp detection methods and optimize polyp detection rates across hospitals. Recent studies document that AI assisted screening improves polyp detection rates and Augere aims to be a trustworthy partner to work towards this goal.
For more information, please contact:
Jon H. Hoem
Executive Chair
Mobile: +41 79 606 2 902
jon@augere.md
About Augere Medical
Augere Medical is a commercial stage Norwegian medical device company founded in 2018 and is developing systems based on Artificial Intelligence (AI) to improve polyp detection rates during screening for colorectal cancer. Augere's first product, the PolypAIdTM System, is being developed in cooperation with leading colonoscopists and in close cooperation with the research group at Simula. The PolypAIdTM System analyses the real-time video stream during colonoscopy screening and supports the physicians in making the right decision during the screening process. The company has received public grants from Innovation Norway and the Research Council of Norway and has now started the European launch of the PolypAIdTM System.
This information was brought to you by Cision http://news.cision.com
The following files are available for download:
|
Press release (PDF) |
View original content:https://www.prnewswire.com/news-releases/augere-medical-secures-mdr-ce-mark-for-its-polypaid-software-and-system-302233845.html
SOURCE Augere Medical AS
First published on Thu, Aug 29, 2024
Liked what you read? That’s only the tip of the tech iceberg!
Explore our vast collection of tech articles including introductory guides, product reviews, trends and more, stay up to date with the latest news, relish thought-provoking interviews and the hottest AI blogs, and tickle your funny bone with hilarious tech memes!
Plus, get access to branded insights from industry-leading global brands through informative white papers, engaging case studies, in-depth reports, enlightening videos and exciting events and webinars.
Dive into TechDogs' treasure trove today and Know Your World of technology like never before!
Disclaimer - Reference to any specific product, software or entity does not constitute an endorsement or recommendation by TechDogs nor should any data or content published be relied upon. The views expressed by TechDogs' members and guests are their own and their appearance on our site does not imply an endorsement of them or any entity they represent. Views and opinions expressed by TechDogs' Authors are those of the Authors and do not necessarily reflect the view of TechDogs or any of its officials. While we aim to provide valuable and helpful information, some content on TechDogs' site may not have been thoroughly reviewed for every detail or aspect. We encourage users to verify any information independently where necessary.
Trending PR Newswire
Cyient Semiconductors Announces Strategic Financing With Edelweiss At ~ USD 500 Mn. Equity Valuation
Jotpsych Launches Jotmeet, An Integrated Telehealth Product
Trapilot.Ai Launches The World's First AI-Native SEO Service Platform
Beacon Mutual Addresses Data Security Incident
Two Seasoned Members Of Huyett's Management Team Promoted To Leadership Committee
Join Our Newsletter
Get weekly news, engaging articles, and career tips-all free!
By subscribing to our newsletter, you're cool with our terms and conditions and agree to our Privacy Policy.
Join The Discussion